BioAtla Inc Ordinary Shares BCAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.95
- Day Range
- $3.66–4.01
- 52-Week Range
- $3.12–71.50
- Bid/Ask
- $3.74 / $4.08
- Shares Outstanding
- 1.66M
- Market Cap
- $6.14M
- Volume/Avg
- 141 / 51,351
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 41
- Website
- https://www.bioatla.com
Valuation
|
Metric
|
BCAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.49 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCAB
|
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.15 |
Interest Coverage | — |
Quick Ratio
BCAB
Profitability
|
Metric
|
BCAB
|
|---|---|
Return on Assets (Normalized) | −226.38% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BCAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|tp>Vx!# | LOCK|@!<^$ | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Q@B@yw | LOCK|l%?%# | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&?ZNd$y | LOCK|%^B | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#RdKVQ? | LOCK|D&B | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?#%<%& | LOCK|>F^c$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^q^DfY^ | LOCK|@!vc | $25B | |||
| Moderna Inc
MRNA
| LOCK|^Q>%#v | LOCK|>BJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|g<%VnQ | LOCK|^k^ | $23B | |||
| Incyte Corp
INCY
| LOCK|qk<W!?M | LOCK|<R | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|hV%yV$ | LOCK|R^@ | $16B |
United States